CoChat

An 8‐year follow‐up of anti‐vascular endothelial growth factor treatment with a treat‐and‐extend modality for neovascular age‐related macular degeneration

Open access
Berg, Karina, Roald, Anca B., Navaratnam, Jesintha, Bragadóttir, Ragnheiður · 2017 · Acta Ophthalmologica
Cited by 69

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Purpose: To investigate long‐term visual results of treatment with anti‐vascular endothelial growth factor (VEGF) agents for neovascular age‐related macular degeneration (nAMD) following a treat‐and‐extend regimen. Methods: Retrospective review of 155 patients who initiated treatment with bevacizumab for nAMD in one eye. At the final 8‐year visit, 40 patients (26%) remained for follow‐up. Mean change in best‐corrected visual acuity (BCVA) was calculated compared to baseline values. Results: Mean BCVA improved significantly from baseline during the first year of treatment, with −0.11 log MAR units equivalent to 6.1 approximate Early Treatment Diabetic Retinopathy Study (approx ETDRS) letters (p = <0.001). Mean BCVA was still significantly improved after 4 years of treatment for the entire group of patients and after 6 years of treatment for the subgroup of 40 patients who remained at the final 8‐year visit. Thereafter, BCVA gradually declined and at 8 years, there was a mean change of 0.05 log MAR units equivalent to 2.1 approx ETDRS letters below baseline (p = 0.530). Mean number of injections during the first year was 6.1 ± 2.8 and during year 8 was 5.4 ± 3.5. At 5 years, fundus autofluorescence showed some degree of macular atrophy in all eyes. At the final 8‐year visit, 87.5% of the eyes had stable neovascular lesions with no fluid on optical coherence tomography (OCT). Conclusion: In an everyday clinical setting, treatment of nAMD patients with a treat‐and‐extend modality provided improvement and stability of vision for several years. After 8 years of follow‐up, there was a decline in visual acuity (VA) that could be explained by macular atrophic development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/aos.13522

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Berg, K., Roald, A. B., Navaratnam, J., & Bragadóttir, R.
Venue
Acta Ophthalmologica
Publisher
Wiley
Published
2017-09-19
Volume
95
Issue
8
Pages
796-802
ISSN
  • 0001-639X (ISSN-L)
  • 1755-375X
  • 1755-3768
OpenAlex
W2754502683
Cited by
69
References
9
FWCI
7.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.